Nanotechnology Now - Press Release: OctoPlus appoints Susan Swarte as Chief Financial Officer

Home > Press > OctoPlus appoints Susan Swarte as Chief Financial Officer

Abstract:
OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery company, announces today that Susan Swarte will join the Company on 1 August as Chief Financial Officer.

OctoPlus appoints Susan Swarte as Chief Financial Officer

The Netherlands | Posted on June 29th, 2009

At the next general meeting of shareholders the Board of Supervisory Directors will propose to appoint Mrs. Swarte as member of the Executive Board for a period of four years. After approval of the shareholders, OctoPlus' Executive Board will consist of Chief Executive Officer Simon Sturge, Chief Financial Officer Susan Swarte, Chief Scientific Officer Joost Holthuis and Chief Business Officer Gerben Moolhuizen.

Susan Swarte (1968) has over 16 years of experience in financial and strategic management. She worked at Unilever and Numico (now Danone), two large, international and publicly listed companies, where she was responsible for financial, logistic and reporting aspects. At Numico she professionalised the finance function in China and most recently she was responsible for all financial aspects of the export business of Danone Baby Nutrition as Finance Director, Global Export.

"We are delighted with the appointment of Susan Swarte," comments Simon Sturge, CEO of OctoPlus. "The Supervisory Board of Directors has nominated Mrs. Swarte based on her international experience and excellent track record in the broad financial management of large public companies. She knows the financial aspects of companies operating large manufacturing facilities inside out and we believe her expertise will greatly benefit OctoPlus. We look forward to welcoming her in Leiden."

This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus and the industry in which it operates. These statements are based on OctoPlus' current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.

####

About OctoPlus N.V.
OctoPlus is a product-oriented biopharmaceutical company committed to the creation of improved pharmaceutical products that are based on OctoPlus' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. Rather than seeking to discover novel drug candidates through early stage research activities, OctoPlus focuses on the development of longer acting, controlled release versions of known protein therapeutics, other drugs, and vaccines on behalf of its clients.

The clinically most advanced product incorporating our technology is Biolex Therapeutics' lead product Locteron®, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. Locteron is being manufactured for Biolex by OctoPlus and is currently in Phase IIb clinical studies.

In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO.

For more information, please click here

Contacts:
Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071, or send an e-mail to Investor Relations at

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: